A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Trial Profile

A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Pimasertib (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck KGaA
  • Most Recent Events

    • 19 Oct 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 19 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
    • 05 Nov 2014 Planned number of patients changed from 48 to 80 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top